Tuberculosis treatment incompletion in patients with lung cancer: occurrence and predictors

Background: Lung cancer patients are high-risk for active tuberculosis (TB); however, fragility and drug-drug interaction might lead to TB treatment interruption. TB treatment incompletion occurrence and predictors among lung cancer patients remain unclear. Methods: We recruited lung cancer patients...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chung-Shu Lee, Chin-Chung Shu, Yi-Chen Chen, Kuang-Ming Liao, Chung-Han Ho
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Tuberculosis Treatment incompletion Lung cancer Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/d23aefa8f6794877ab60d4eecfa719f0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d23aefa8f6794877ab60d4eecfa719f0
record_format	dspace
spelling	oai:doaj.org-article:d23aefa8f6794877ab60d4eecfa719f02021-11-10T04:21:19ZTuberculosis treatment incompletion in patients with lung cancer: occurrence and predictors1201-971210.1016/j.ijid.2021.09.072https://doaj.org/article/d23aefa8f6794877ab60d4eecfa719f02021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1201971221007839https://doaj.org/toc/1201-9712Background: Lung cancer patients are high-risk for active tuberculosis (TB); however, fragility and drug-drug interaction might lead to TB treatment interruption. TB treatment incompletion occurrence and predictors among lung cancer patients remain unclear. Methods: We recruited lung cancer patients with new-onset TB from Taiwan Cancer Registry and Taiwanese National Health Insurance 2007–2015 databases. TB treatment incompletion was the identified primary outcome, and associated risk factors were analyzed. Results: A total of 1155 lung cancer patients with new-onset TB were identified and classified as treatment incompletion (n=706, 61.13%) or completion (n=449). Gender and age distribution was similar in both groups. Under multivariable logistic regression, advanced cancer (stage III and IV) and no first-line TB drugs use were independent factors for treatment incompletion; but older age was not significant. For patients surviving >1 year since TB diagnosis, independent factors for treatment incompletion included no first-line TB drugs use (except pyrazinamide) and absence of hypertension. Cancer stage had borderline significance. Conclusions: TB treatment incompletion occurred in 61.13% of lung cancer patients. Clinicians should carefully titrate anti-TB medications and monitor side effects in lung cancer patients, especially those with treatment incompletion risk factors, to avoid treatment interruption due to fragility and/or drug intolerance.Chung-Shu LeeChin-Chung ShuYi-Chen ChenKuang-Ming LiaoChung-Han HoElsevierarticleTuberculosisTreatment incompletionLung cancerInfectious and parasitic diseasesRC109-216ENInternational Journal of Infectious Diseases, Vol 113, Iss , Pp 200-206 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Tuberculosis Treatment incompletion Lung cancer Infectious and parasitic diseases RC109-216
spellingShingle	Tuberculosis Treatment incompletion Lung cancer Infectious and parasitic diseases RC109-216 Chung-Shu Lee Chin-Chung Shu Yi-Chen Chen Kuang-Ming Liao Chung-Han Ho Tuberculosis treatment incompletion in patients with lung cancer: occurrence and predictors
description	Background: Lung cancer patients are high-risk for active tuberculosis (TB); however, fragility and drug-drug interaction might lead to TB treatment interruption. TB treatment incompletion occurrence and predictors among lung cancer patients remain unclear. Methods: We recruited lung cancer patients with new-onset TB from Taiwan Cancer Registry and Taiwanese National Health Insurance 2007–2015 databases. TB treatment incompletion was the identified primary outcome, and associated risk factors were analyzed. Results: A total of 1155 lung cancer patients with new-onset TB were identified and classified as treatment incompletion (n=706, 61.13%) or completion (n=449). Gender and age distribution was similar in both groups. Under multivariable logistic regression, advanced cancer (stage III and IV) and no first-line TB drugs use were independent factors for treatment incompletion; but older age was not significant. For patients surviving >1 year since TB diagnosis, independent factors for treatment incompletion included no first-line TB drugs use (except pyrazinamide) and absence of hypertension. Cancer stage had borderline significance. Conclusions: TB treatment incompletion occurred in 61.13% of lung cancer patients. Clinicians should carefully titrate anti-TB medications and monitor side effects in lung cancer patients, especially those with treatment incompletion risk factors, to avoid treatment interruption due to fragility and/or drug intolerance.
format	article
author	Chung-Shu Lee Chin-Chung Shu Yi-Chen Chen Kuang-Ming Liao Chung-Han Ho
author_facet	Chung-Shu Lee Chin-Chung Shu Yi-Chen Chen Kuang-Ming Liao Chung-Han Ho
author_sort	Chung-Shu Lee
title	Tuberculosis treatment incompletion in patients with lung cancer: occurrence and predictors
title_short	Tuberculosis treatment incompletion in patients with lung cancer: occurrence and predictors
title_full	Tuberculosis treatment incompletion in patients with lung cancer: occurrence and predictors
title_fullStr	Tuberculosis treatment incompletion in patients with lung cancer: occurrence and predictors
title_full_unstemmed	Tuberculosis treatment incompletion in patients with lung cancer: occurrence and predictors
title_sort	tuberculosis treatment incompletion in patients with lung cancer: occurrence and predictors
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/d23aefa8f6794877ab60d4eecfa719f0
work_keys_str_mv	AT chungshulee tuberculosistreatmentincompletioninpatientswithlungcanceroccurrenceandpredictors AT chinchungshu tuberculosistreatmentincompletioninpatientswithlungcanceroccurrenceandpredictors AT yichenchen tuberculosistreatmentincompletioninpatientswithlungcanceroccurrenceandpredictors AT kuangmingliao tuberculosistreatmentincompletioninpatientswithlungcanceroccurrenceandpredictors AT chunghanho tuberculosistreatmentincompletioninpatientswithlungcanceroccurrenceandpredictors
_version_	1718440695301144576

Tuberculosis treatment incompletion in patients with lung cancer: occurrence and predictors

Ejemplares similares